Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VENU vs MDCX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MDCX Captures Overall Composite Edge (49.2 HOLD vs 42.3 HOLD), While VENU Leads 3–2 on Growth & Valuation Pillars

MDCX Overall Winner 6-Pillar Tally: VENU 3 – 2 MDCX (1 Tie) Matrix Metrics: VENU 4 – 4 MDCX

As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) captures the overall head-to-head institutional edge over Venu Holding Corporation (VENU) on higher Unified Composite conviction (49.2/100 HOLD vs. 42.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while VENU wins 3–2 across the 6-pillar growth and valuation breakdown. VENU trades at $0.99 (N/M Forward P/E, -294.7% operating margin) versus MDCX at $1.14 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: MDCX earns the overall head-to-head edge with a stronger Unified Composite Score (49.2/100 HOLD vs. VENU 42.3/100 HOLD) and -0.28β · 118% Vol risk profile, whereas VENU leads top-line expansion (+2.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VENU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1); meanwhile MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VENU vs MDCX
VENU NYSE American
Venu Holding Corporation
Services-Amusement & Recreation Services
$0.99
-3.6% 1D
Market Cap $58.3M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 1.72β · 86% Vol
Unified Composite Score
42.3 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 55.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $1.23 · SMA50: $1.34
MDCX NASDAQ Head-to-Head Winner
Medicus Pharma Ltd. Common Stock
Pharmaceutical Preparations
$1.14
-2.16% 1D
Market Cap $3.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.28β · 118% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 36.1 · SMA20: $1.85 · SMA50: $1.40

6-Pillar Scorecard Institutional Category Breakdown (VENU 3 – 2 MDCX)

Columns: Metric · VENU · MDCX
1. Valuation Multiples VENU
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 12.1x N/M
2. Growth & Scale VENU
Revenue Growth (YoY) +2.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $19M N/A
Market Cap $58.3M $3.1M
3. Profitability & Quality MDCX
Gross Margin 16.4% N/A
Operating Margin -294.7% 0.0%
Net Profit Margin -281.4% 0.0%
Return on Equity (ROE) -24.9% -7446.1%
4. Balance Sheet & Cash Flow MDCX
Cash Generation (TTM) -$46M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $167M Net Debt (1.22x D/E) $3.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VENU
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 76.0% (<1st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Restaurants Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VENU (4) vs MDCX (4)
Institutional Metric VENU MDCX Criterion Row Edge
Market Capitalization
Scale
$58.3M $3.1M Larger Scale VENU
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+2.9% +0.0% Higher Growth VENU
Operating Margin (TTM)
Profitability
-294.7% 0.0% Higher Margin MDCX
Net Profit Margin
Profitability
-281.4% 0.0% Higher Margin MDCX
Return on Equity (ROE)
Capital Efficiency
-24.9% -7446.1% Higher ROE VENU
52-Week Range Position
Momentum
1% ($1–$11) 23% ($0–$5) Stronger Trend MDCX
Beta / 30D Volatility
Risk Regime
1.72β · 86% Vol -0.28β · 118% Vol Lower Realized Risk VENU
Unified Institutional Score
Composite Signal
42.3 / 100 (HOLD) 49.2 / 100 (HOLD) Higher Composite MDCX
Trailing 12M Revenue (USD)
Operating Scale
$19M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
16.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 12.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$46M EBITDA ($167M Net Debt (1.22x D/E)) N/A ($3.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VENU +33.65 pp
VENU: -23.03% · MDCX: -56.68%
3M Horizon MDCX +386.69 pp
VENU: -45.74% · MDCX: +340.95%
6M Horizon MDCX +351.99 pp
VENU: -73.66% · MDCX: +278.33%
1Y Horizon MDCX +40.48 pp
VENU: -89.81% · MDCX: -49.33%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VENU vs MDCX. Trailing 12-month operating profitability (VENU -294.7% vs MDCX 0.0%) and valuation multiples (VENU N/M vs MDCX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VENU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$19M
Gross Margin16.4%
Op. Margin-294.7%
ROE / Fwd P/E-24.9% · N/M
MDCX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-7446.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VENU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VENU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MDCX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MDCX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VENU Moat Profile Cyclical / Execution-Driven Positioning
Restaurants Operator
Competes within the Restaurants value chain with $58.3M market capitalization and -294.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MDCX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $3.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VENU vs MDCX Key Questions & Quantitative Answers

As of Nov 20, 2026, Medicus Pharma Ltd. (MDCX) captures the overall head-to-head institutional edge over Venu Holding Corporation (VENU) on higher Unified Composite conviction (49.2/100 HOLD vs. 42.3/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while VENU wins 3–2 across the 6-pillar growth and valuation breakdown. VENU trades at $0.99 (N/M Forward P/E, -294.7% operating margin) versus MDCX at $1.14 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: MDCX earns the overall head-to-head edge with a stronger Unified Composite Score (49.2/100 HOLD vs. VENU 42.3/100 HOLD) and -0.28β · 118% Vol risk profile, whereas VENU leads top-line expansion (+2.9% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VENU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1); meanwhile MDCX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 36.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VENU leads the Growth & Scale pillar: VENU posts +2.9% YoY revenue growth and +0.0% YoY earnings growth on $19M TTM revenue (16.4% gross margin, -294.7% operating margin), compared with MDCX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VENU generates $19M in USD-normalized revenue versus N/A for MDCX. In operating R&D and SG&A reinvestment, VENU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MDCX.

VENU screens cheaper on headline valuation multiples. VENU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.1x EV/Revenue (unreported EBITDA margin), whereas MDCX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VENU (-24.9% ROE) versus MDCX (-7446.1% ROE) capital efficiency.

In options market volatility and institutional positioning, VENU carries 76.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.72β · 86% Vol realized risk). By comparison, MDCX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.28β · 118% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.